http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S59128327-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1374dd16777534b65ad4422333245af8 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-557 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 1983-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a3e031c2c78c88ee6aed81c1b9b7b78 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc73a53703b5cdb6582ae13ea7614f2c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05c770f8fe49600c6a4da6a0e813be59 |
| publicationDate | 1984-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-S59128327-A |
| titleOfInvention | Drug for transcutaneous administration containing 7-thiaprostaglandin e1 compound |
| abstract | PURPOSE: To provide the titled drug containing 7-thiaprostaglandin E 1 as an active component, useful for the remedy of diseases of peripheral vessels, and free of side effects inherent to the oral administration or intracutaneous administration. n CONSTITUTION: The titled transcutaneous drug is an ointment, cream, lotion, or solution containing the 7-thiaprostaglandin E 1 compound of formula (R 1 is H, lower alkyl or cation; R 2 is H or methyl; R 3 is 5W8C alkyl or 5W8C cycloalkyl) as an active component. Although 7-thiaprostaglandin E 1 compound has excellent pharmacological effects such as vessel dilating, hypotensive, and blood platelet coagulation inhibiting activities, etc., it is difficult to restrict the drug action to the diseased part by oral administration, and the intracutaneous administration causes the pain of the skin. The drug action of the present drug can be localized to the diseased part by transcutaneous administration, is favorably comparable to that of the oral administration, and lasts for a long period. n COPYRIGHT: (C)1984,JPO&Japio |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0722733-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9520391-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7888392-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006085655-A1 |
| priorityDate | 1983-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393636 |
Total number of triples: 22.